Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
About this trial
This is an interventional treatment trial for Leukemia focused on measuring chronic myelomonocytic leukemia, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, de novo myelodysplastic syndromes, atypical chronic myeloid leukemia, myelodysplastic/myeloproliferative disease, unclassifiable
Eligibility Criteria
DISEASE CHARACTERISTICS: Morphologically and cytogenetically confirmed myelodysplastic syndromes or chronic myelomonocytic leukemia No more than 20% blasts by bone marrow biopsy Must meet at least 1 of the following criteria: Anemia Hemoglobin less than 11 g/dL over a 2-month period Thrombocytopenia Neutropenia PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic See Disease Characteristics Hepatic ALT and AST less than 1.5 times upper limit of normal Bilirubin less than 3 mg/dL Albumin greater than 3.0 g/dL Renal Creatinine clearance greater than 50 mL/min No history of hypercalcemia No renal stones within the past 5 years Cardiovascular No clinically significant heart failure No uncontrolled hypertension Pulmonary No clinically significant pulmonary failure Other Not pregnant Fertile patients must use effective contraception during and for 6 months after study PRIOR CONCURRENT THERAPY: Biologic therapy At least 4 weeks since prior growth factor or cytokine therapy Chemotherapy At least 8 weeks since prior cytotoxic chemotherapy Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other Concurrent transfusion support allowed
Sites / Locations
- University of Wisconsin Comprehensive Cancer Center